SCHEMBL25327965

SCHEMBL25327965

CS(=O)(=O)c1cccc(COC2CN(C(=O)N3CC4(CC(c5nnc(C6CC6)[nH]5)C4)C3)C2)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FAAH O00519 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ F10 P00742 1/20 0.34
▸ ENPP2 Q13822 2/20 0.33
▸ ATXN2 Q99700 2/20 0.33
▸ DRD2 P14416 1/20 0.32
▸ ALOX5AP P20292 1/20 0.32
▸ FEN1 P39748 1/20 0.32
▸ GRM2 Q14416 2/20 0.32
▸ GRM3 Q14832 2/20 0.32
▸ MAPK1 P28482 1/20 0.32
▸ ROCK2 O75116 1/20 0.32
▸ GPR119 Q8TDV5 2/20 0.31
▸ OPRM1 P35372 1/20 0.31
▸ OPRL1 P41146 1/20 0.31
▸ KMT2A Q03164 1/20 0.31
▸ CYP4F2 P78329 1/20 0.31
▸ CYP4A11 Q02928 1/20 0.31
▸ MMP2 P08253 1/20 0.31
▸ MMP13 P45452 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25324941 0.90 GPR119 (0.36) FAAHENPP2ATXN2GPR119
SCHEMBL25324593 0.89 MGLL (0.37) FAAHENPP2ATXN2MGLL
SCHEMBL25326033 0.85 MGLL (0.37) DRD2GRM2GRM3MAPK1OPRM1
SCHEMBL25325310 0.85 GPR119 (0.38) FAAHENPP2ATXN2GPR119MGLL
SCHEMBL25324298 0.84 DRD2 (0.40) FAAHDRD2GRM2GRM3ROCK2
SCHEMBL25324985 0.83 FAAH (0.41) FAAHF10KMT2AMGLL
SCHEMBL25323899 0.82 DRD2 (0.43) FAAHENPP2ATXN2DRD2ROCK2
SCHEMBL25324987 0.82 OPRM1 (0.35) DRD2ALOX5APFEN1GRM2GRM3
SCHEMBL25324021 0.80 MGLL (0.38) FAAHENPP2ATXN2MGLL
SCHEMBL25327267 0.80 MGLL (0.36) ENPP2ATXN2KMT2AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US claimed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP claimed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO claimed
US-20250099448-A1 HETEROCYCLIC COMPOUNDS HOFFMANN-LA ROCHE INC. (US) 2025-03-27 — — US disclosed
EP-4469446-A1 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-04 — — EP disclosed
WO-2023144160-A1 NEW HETEROCYCLIC COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250099448-A1 HETEROCYCLIC COMPOUNDS OPRM1, CYP1A1, CYP3A4 FAAH 451/4885SLC6A4 609/4885F10 1170/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback